The drug industry has been gradually migrating to the cloud for years. But the Covid-19 pandemic has rapidly accelerated that shift for a simple reason: Researchers needed to run the biggest experiment of their lives in record time, and they lacked the power to launch it.
In recent months, pharma companies have struck deals with tech giants like Amazon, Google, and Microsoft, which sell cloud services that could provide the computing power urgently needed to search vast libraries of molecules for a potential cure. Drug companies say transitioning to the cloud has cut down the time needed for certain research efforts from months to mere days — precious time as the global health crisis rages on.
Among those turning to the cloud is UCB, a Belgian drug company that was using AI to search for a potential Covid-19 treatment as part of a global initiative known as the COVID Moonshot.
This article is exclusive to STAT+ subscribers
Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect